[Effect of low-molecular heparin on blood coagulation].
The coagulation-inhibiting effect of subcutaneously administered commercial and a low-molecular heparin was compared in healthy volunteers. Global clotting activity, measured as activated partial thromboplastin time as well as thrombin activity were inhibited almost equally by commercial and low-molecular heparin. Low-molecular heparin caused a ten-fold stronger inhibition of factor Xa. The effect on factor Xa increased nearly logarithmically with the injected dose. Half-life of heparin measured in terms of the inhibition of factor Xa was 5.5 hours for the low-molecular and 3.5 hours for the commercial preparation. These results indicate that low-molecular heparin has a high specificity in the inhibition of factor Xa. A lower dose of low-molecular heparin, administered once daily, may have an anti-thrombotic effect while reducing the risk of bleeding.
D000328:Adult; D001777:Blood Coagulation / Q000187:drug effects*; D005170:Factor X / Q000037:antagonists & inhibitors; D006207:Half-Life; D006470:Hemorrhage / Q000517:prevention & control; D006493:Heparin / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D008970:Molecular Weight; D013927:Thrombosis / Q000517:prevention & control
D005170:Factor X; D006493:Heparin
Beeinflussung der Blutgerinnung durch ein niedermolekulares Heparin.